Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))

Aaron T. Gerds; Tetsuzo Tauchi; Ellen Ritchie; Michael Deininger; Catriona Jamieson; Ruben Mesa; Mark Heaney; Norio Komatsu; Hironobu Minami; Yun Su; Naveed Shaik; Xiaoxi Zhang; Christine DiRienzo; Mirjana Zeremski; Geoffrey Chan; Moshe Talpaz

doi:10.1016/j.leukres.2019.04.006

Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))

Aaron T. Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Ruben Mesa, Mark Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Geoffrey Chan, Moshe Talpaz

Department of Medicine

Resultado de la investigación: Comment/debate › revisión exhaustiva

Resumen

The authors regret that there is an error in the email address of the corresponding author. Dr. Gerds' correct email address is gerdsa@ccf.org. The authors would like to apologise for any inconvenience caused.

Idioma original	English (US)
Páginas (desde-hasta)	105
Número de páginas	1
Publicación	Leukemia Research
Volumen	81
DOI	https://doi.org/10.1016/j.leukres.2019.04.006
Estado	Published - jun 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Acceder al documento

10.1016/j.leukres.2019.04.006

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))'. En conjunto forman una huella única.

Citar esto

Gerds, A. T., Tauchi, T., Ritchie, E., Deininger, M., Jamieson, C., Mesa, R., Heaney, M., Komatsu, N., Minami, H., Su, Y., Shaik, N., Zhang, X., DiRienzo, C., Zeremski, M., Chan, G., & Talpaz, M. (2019). Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012)). Leukemia Research, 81, 105. https://doi.org/10.1016/j.leukres.2019.04.006

Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012)). / Gerds, Aaron T.; Tauchi, Tetsuzo; Ritchie, Ellen et al.

En: Leukemia Research, Vol. 81, 06.2019, p. 105.

Resultado de la investigación: Comment/debate › revisión exhaustiva

Gerds, AT, Tauchi, T, Ritchie, E, Deininger, M, Jamieson, C, Mesa, R, Heaney, M, Komatsu, N, Minami, H, Su, Y, Shaik, N, Zhang, X, DiRienzo, C, Zeremski, M, Chan, G & Talpaz, M 2019, 'Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))', Leukemia Research, vol. 81, pp. 105. https://doi.org/10.1016/j.leukres.2019.04.006

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R et al. Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012)). Leukemia Research. 2019 jun;81:105. doi: 10.1016/j.leukres.2019.04.006

Gerds, Aaron T. ; Tauchi, Tetsuzo ; Ritchie, Ellen et al. / Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012)). En: Leukemia Research. 2019 ; Vol. 81. pp. 105.

@article{1d2c0c9c5e9b41cc8702db15e8bd2ae8,

title = "Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))",

abstract = "The authors regret that there is an error in the email address of the corresponding author. Dr. Gerds' correct email address is gerdsa@ccf.org. The authors would like to apologise for any inconvenience caused.",

author = "Gerds, {Aaron T.} and Tetsuzo Tauchi and Ellen Ritchie and Michael Deininger and Catriona Jamieson and Ruben Mesa and Mark Heaney and Norio Komatsu and Hironobu Minami and Yun Su and Naveed Shaik and Xiaoxi Zhang and Christine DiRienzo and Mirjana Zeremski and Geoffrey Chan and Moshe Talpaz",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = jun,

doi = "10.1016/j.leukres.2019.04.006",

language = "English (US)",

volume = "81",

pages = "105",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44] (Leukemia Research (2019) 79 (38–44), (S0145212619300384), (10.1016/j.leukres.2019.02.012))

AU - Gerds, Aaron T.

AU - Tauchi, Tetsuzo

AU - Ritchie, Ellen

AU - Deininger, Michael

AU - Jamieson, Catriona

AU - Mesa, Ruben

AU - Heaney, Mark

AU - Komatsu, Norio

AU - Minami, Hironobu

AU - Su, Yun

AU - Shaik, Naveed

AU - Zhang, Xiaoxi

AU - DiRienzo, Christine

AU - Zeremski, Mirjana

AU - Chan, Geoffrey

AU - Talpaz, Moshe

PY - 2019/6

Y1 - 2019/6

N2 - The authors regret that there is an error in the email address of the corresponding author. Dr. Gerds' correct email address is gerdsa@ccf.org. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that there is an error in the email address of the corresponding author. Dr. Gerds' correct email address is gerdsa@ccf.org. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85064532789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064532789&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2019.04.006

DO - 10.1016/j.leukres.2019.04.006

M3 - Comment/debate

C2 - 31029462

AN - SCOPUS:85064532789

SN - 0145-2126

VL - 81

SP - 105

JO - Leukemia Research

JF - Leukemia Research

ER -